Revenues

9 Months Ended

Sep. 30, 2023

Revenues [Abstract]

Revenues

4. Revenues

During the three and nine months ended September 30, 2023 and 2022, our revenues were comprised of the following (in thousands):

	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022
Revenue:
Commercial revenue:
SPINRAZA royalties	$	67,253	$	61,647	$	178,511	$	175,092
Other commercial revenue:
TEGSEDI and WAYLIVRA revenue, net		8,286		5,920		25,420		22,467
Licensing and other royalty revenue		8,542		4,843		25,815		25,320
Total other commercial revenue		16,828		10,763		51,235		47,787
Total commercial revenue		84,081		72,410		229,746		222,879
Research and development revenue:
Collaborative agreement revenue		44,167		69,250		173,513		157,282
Eplontersen joint development revenue		15,959		18,107		59,883		55,317
Total research and development revenue		60,126		87,357		233,396		212,599
Total revenue	$	144,207	$	159,767	$	463,142	$	435,478

Refer to Note 5, Collaborative Arrangements and Licensing Agreements, for further details on our collaborative agreement revenue.